Reviewing Karyopharm Therapeutics Inc. (KPTI)’s and Chimerix Inc. (NASDAQ:CMRX)’s results

We will be contrasting the differences between Karyopharm Therapeutics Inc. (NASDAQ:KPTI) and Chimerix Inc. (NASDAQ:CMRX) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Karyopharm Therapeutics Inc. 18 0.19 34.71M -3.42 0.00
Chimerix Inc. 2 0.00 43.71M -2.25 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Karyopharm Therapeutics Inc. 194,344,904.82% -187.2% -71.9%
Chimerix Inc. 2,035,010,940.92% -82.3% -75.2%

Volatility & Risk

A beta of 2.55 shows that Karyopharm Therapeutics Inc. is 155.00% more volatile than Standard and Poor’s 500. Competitively, Chimerix Inc.’s beta is 1.48 which is 48.00% more volatile than Standard and Poor’s 500.


The Current Ratio of Karyopharm Therapeutics Inc. is 7.2 while its Quick Ratio stands at 7.2. The Current Ratio of rival Chimerix Inc. is 8.2 and its Quick Ratio is has 8.2. Chimerix Inc. is better equipped to clear short and long-term obligations than Karyopharm Therapeutics Inc.

Analyst Ratings

Karyopharm Therapeutics Inc. and Chimerix Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Karyopharm Therapeutics Inc. 0 0 3 3.00
Chimerix Inc. 0 0 0 0.00

Karyopharm Therapeutics Inc. has a 28.64% upside potential and an average price target of $23.67.

Institutional & Insider Ownership

The shares of both Karyopharm Therapeutics Inc. and Chimerix Inc. are owned by institutional investors at 92.99% and 63.5% respectively. Insiders held roughly 2.1% of Karyopharm Therapeutics Inc.’s shares. Comparatively, insiders own roughly 17.3% of Chimerix Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Karyopharm Therapeutics Inc. -7.02% 16.19% 68.11% 176.57% 59.86% 73.85%
Chimerix Inc. 11.82% 59.74% 18.84% -27% -23.6% -4.28%

For the past year Karyopharm Therapeutics Inc. has 73.85% stronger performance while Chimerix Inc. has -4.28% weaker performance.


On 6 of the 11 factors Chimerix Inc. beats Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companyÂ’s lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.